Myfortic for Type 1 Diabetes Islet Transplant Recipients

This trial tests a medication called Myfortic to assist individuals who have had islet transplants for type 1 diabetes but have lost transplant function. The focus is on determining if Myfortic can improve their condition by managing the immune system response. Individuals who have had at least one islet transplant and currently require immunosuppressive medication are suitable candidates for this trial. As an unphased trial, this study provides a unique opportunity for participants to contribute to innovative research that could enhance transplant outcomes.

The trial does not specify if you need to stop taking your current medications, but it mentions that participants may be on immunosuppressive medications or may need to stop them as per the current protocol of islet transplantation.

Research has shown that Myfortic has been studied in various contexts, including with kidney transplant patients. One study involving 423 kidney transplant recipients used Myfortic to help prevent organ rejection. These patients, aged 18 to 75, came from several countries, including the USA and Canada. This study provides insight into how well people tolerate Myfortic.

Generally, Myfortic is well-tolerated, but like any medication, it can cause side effects. Common side effects include stomach problems, headaches, and infections. Notably, the FDA has approved this medication for use in kidney transplant patients, indicating substantial safety information supports its use in this context.

Unlike the standard treatments for Type 1 diabetes in islet transplant recipients, Myfortic offers a new approach by focusing on immune system modulation. Most current therapies aim to manage blood sugar levels or suppress the immune system broadly, but Myfortic specifically targets the immune pathways involved in transplant rejection. This precision could lead to fewer side effects and better outcomes for patients, making it an exciting option for researchers looking to improve transplant success rates.

Research has shown that Myfortic, which contains mycophenolic acid, plays a crucial role in transplants by preventing the immune system from attacking new cells. Previous studies have found that islet transplants in people with type 1 diabetes can lead to insulin independence, eliminating the need for insulin shots. In some cases, all patients became insulin independent, and many maintained this status for an extended period. This trial will evaluate Myfortic's role in supporting islet transplants, potentially improving blood sugar control and reducing episodes of low blood sugar in type 1 diabetes.²⁴⁶⁷⁸